Catalyst Pharmaceuticals (CPRX) Equity Average (2011 - 2026)

Catalyst Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at $983.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 29.24% year-over-year to $983.5 million; the trailing twelve-month figure through Mar 2026 stood at $983.5 million (up 29.24% YoY), and the FY2025 full-year result was $841.0 million, up 50.77% from the prior year.
• Equity Average for Q1 2026 stood at $983.5 million, up from $937.3 million in the prior quarter.
• The five-year high for Equity Average was $983.5 million in Q1 2026, with the low at $213.5 million in Q1 2022.
• Historically, Equity Average has averaged $539.4 million across 5 years, with a median of $474.6 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average advanced 22.63% — and 2024, when it soared 88.55%.
• Catalyst Pharmaceuticals' Equity Average stood at $285.2 million in 2022, then gained by 29.09% to $368.2 million in 2023, then soared by 88.55% to $694.3 million in 2024, then soared by 35.0% to $937.3 million in 2025, then gained by 4.93% to $983.5 million in 2026.
• The last three Equity Average figures came in at $983.5 million (Q1 2026), $937.3 million (Q4 2025), and $888.1 million (Q3 2025), per Business Quant data.